Paris, France May 21, 2026 – Key patents for semaglutide-based GLP-1 therapies are beginning to lapse, which is accelerating the expansion of the global generic drug market. Cypheme has urged producers to implement AI-driven authentication standards to secure supply chains and protect patient safety. This announcement coincides with ongoing alerts from regulatory bodies, including the U.S. Food and Drug Administration and Australia’s Therapeutic Goods Administration, regarding counterfeit GLP-1 products infiltrating legitimate distribution networks.
As the generic GLP-1 sector grows globally, the lack of a universal authentication framework is creating a significant weakness: counterfeit medicines that are often visually identical to authentic products. According to the World Health Organization, an estimated 1 in 10 medical products in low- and middle-income nations is substandard or falsified, highlighting the scale of the global counterfeit drug issue. Regulatory agencies have also increased import alerts and seizures linked to falsified pharmaceuticals, indicating rising pressure on supply chain integrity as demand increases.
Cypheme is addressing this issue with its proprietary Noise Print technology, positioning it as a “Digital Certificate of Origin” for pharmaceutical packaging. Applied directly to product labels or packaging, Noise Print allows for instant verification using a standard smartphone camera; no specialized equipment is required. The company argues that for legitimate generic producers, verifiable packaging is not a regulatory burden but a competitive advantage by offering a clear, scalable method to distinguish trusted products in an increasingly crowded and risk-prone market.
“The generic pharmaceutical industry is reaching a defining moment,” said Hugo Garcia-Cotte, CEO of Cypheme. “Manufacturers who build trust through transparency will define the category. Those who do not will be indistinguishable from the counterfeiters they are competing against.”
Cypheme has also announced that it is actively collaborating with generic GLP-1 manufacturers to pilot authentication standards ahead of the expected 2026-2027 market expansion. These pilot initiatives aim to establish a new baseline for product verification, aligning with regulatory expectations while reinforcing consumer confidence at scale.
About Cypheme
Cypheme is a global leader in AI-powered anti-counterfeiting technology, providing brands and governments with advanced tools to verify product authenticity and combat fraud. Its patented Noise Print technology enables instant, smartphone-based authentication and delivers actionable insights through geolocation intelligence and data analytics. Endorsed by international institutions and trusted across industries, including pharmaceuticals, Cypheme helps organizations protect revenue, strengthen supply chains, and ensure consumer safety.
For more information, visit: https://www.cypheme.com/
Media Contact:
Cypheme Communications
Email: help@cypheme.com
Address: 5 Parvis Alan Turing, 75013 Paris, France
Media Contact
Cypheme
*****@cypheme.com
https://www.cypheme.com/
Source :Cypheme
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.